mRNA vaccines against infectious diseases and future direction

被引：3
作者：
Aleem, Muhammad Tahir [1 ,3 ]
Munir, Furqan [2 ]
Shakoor, Amna [4 ]
Gao, Fenfei [1 ]
机构：
[1] Shantou Univ, Med Coll, Dept Pharmacol, Shantou 515041, Peoples R China
[2] Univ Agr Faisalabad, Fac Vet Sci, Dept Parasitol, Faisalabad 38040, Pakistan
[3] Cleveland State Univ, Dept Biol Geol & Environm Sci, Coll Sci & Hlth Profess, Ctr Gene Regulat Hlth & Dis, Cleveland, OH 44115 USA
[4] Univ Agr Faisalabad, Fac Vet Sci, Dept Anat, Faisalabad 38040, Pakistan
来源：
INTERNATIONAL IMMUNOPHARMACOLOGY | 2024年 / 135卷
关键词：
Immunogenicity; mRNA vaccine delivery; Infectious diseases; mRNA constructs; IMMUNE-RESPONSES; PROTECTIVE IMMUNITY; RABIES VACCINE; SYNTHETIC RNA; VIRUS; DELIVERY; IMMUNOGENICITY; INDUCTION; TOXOPLASMOSIS; NANOPARTICLES;
D O I：
10.1016/j.intimp.2024.112320
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Vaccines are used for the control of infectious diseases of animals. Over other types of vaccinations like live attenuated or killed vaccines, mRNA-based vaccines have significant advantages. As only a small portion of the pathogen's genetic material is employed and the dose rate of mRNA-based vaccines is low, there is the least possibility that the pathogen will reverse itself. A carrier or vehicle that shields mRNA-based vaccines from the host's cellular RNases is necessary for their delivery. mRNA vaccines have been shown to be effective and to induce both a cell-mediated immune response and a humoral immune response in clinical trials against various infectious diseases (viral and parasitic) affecting the animals, including rabies, foot and mouth disease, toxoplasmosis, Zikavirus, leishmaniasis, and COVID-19. The current review aims to highlight the use of mRNA-based vaccines both in viral and parasitic diseases of animals.
引用
收藏
页数：9
相关论文
共 88 条
  • [1] Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
    Alberer, Martin
    Gnad-Vogt, Ulrike
    Hong, Henoch Sangjoon
    Mehr, Keyvan Tadjalli
    Backert, Linus
    Finak, Greg
    Gottardo, Raphael
    Bica, Mihai Alexandru
    Garofano, Aurelio
    Koch, Sven Dominik
    Fotin-Mleczek, Mariola
    Hoerr, Ingmar
    Clemens, Ralf
    von Sonnenburg, Frank
    [J]. LANCET, 2017, 390 (10101) : 1511 - 1520
  • [2] Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
    Aldrich, Cassandra
    Leroux-Roels, Isabel
    Huang, Katell Bidet
    Bica, Mihai Alexandru
    Loeliger, Edde
    Schoenborn-Kellenberger, Oliver
    Walz, Lisa
    Leroux-Roels, Geert
    von Sonnenburg, Frank
    Oostvogels, Lidia
    [J]. VACCINE, 2021, 39 (08) : 1310 - 1318
  • [3] Flow of Zoonotic Toxoplasmosis in Food Chain
    Almuzaini, Abdulaziz M.
    [J]. PAKISTAN VETERINARY JOURNAL, 2023, 43 (01) : 1 - 16
  • [4] Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies
    Armbruster, Nicole
    Jasny, Edith
    Petsch, Benjamin
    [J]. VACCINES, 2019, 7 (04)
  • [5] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
  • [6] Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development
    Begum, Jubeda
    Mir, Nasir Akbar
    Dev, Kapil
    Buyamayum, Bidyarani
    Wani, Mohd Yaqoob
    Raza, Meesam
    [J]. TRANSBOUNDARY AND EMERGING DISEASES, 2021, 68 (03) : 1111 - 1124
  • [7] Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach
    Bhattacharya, Manojit
    Sharma, Ashish Ranjan
    Ghosh, Pratik
    Patra, Prasanta
    Patra, Bidhan Chandra
    Lee, Sang-Soo
    Chakraborty, Chiranjib
    [J]. MOLECULAR BIOTECHNOLOGY, 2022, 64 (05) : 510 - 525
  • [8] An Update on Self-Amplifying mRNA Vaccine Development
    Blakney, Anna K.
    Ip, Shell
    Geall, Andrew J.
    [J]. VACCINES, 2021, 9 (02) : 1 - 26
  • [9] An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection
    Bollman, Brooke
    Nunna, Naveen
    Bahl, Kapil
    Hsiao, Chiaowen Joyce
    Bennett, Hamilton
    Butler, Scott
    Foreman, Bryant
    Burgomaster, Katherine E.
    Aleshnick, Maya
    Kong, Wing-Pui
    Fisher, Brian E.
    Ruckwardt, Tracy J.
    Morabito, Kaitlyn M.
    Graham, Barney S.
    Dowd, Kimberly A.
    Pierson, Theodore C.
    Carfi, Andrea
    [J]. NPJ VACCINES, 2023, 8 (01)
  • [10] Isolation of Infective Zika Virus from Urine and Saliva of Patients in Brazil
    Bonaldo, Myrna C.
    Ribeiro, Ieda P.
    Lima, Noemia S.
    dos Santos, Alexandre A. C.
    Menezes, Lidiane S. R.
    da Cruz, Stephanie O. D.
    de Mello, Iasmim S.
    Furtado, Nathalia D.
    de Moura, Elaine E.
    Damasceno, Luana
    da Silva, Kely A. B.
    de Castro, Marcia G.
    Gerber, Alexandra L.
    de Almeida, Luiz G. P.
    Lourenco-de-Oliveira, Ricardo
    Vasconcelos, Ana Tereza R.
    Brasil, Patricia
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2016, 10 (06):
123456789